These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29488681)

  • 21. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles].
    Suzuki Inoue K; Inoue O; Ozaki Y
    Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.
    Suzuki-Inoue K; Osada M; Ozaki Y
    J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rhodocytin, a functional novel platelet agonist belonging to the heterodimeric C-type lectin family, induces platelet aggregation independently of glycoprotein Ib.
    Shin Y; Morita T
    Biochem Biophys Res Commun; 1998 Apr; 245(3):741-5. PubMed ID: 9588185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β.
    Moroi AJ; Watson SP
    J Thromb Haemost; 2015 Jun; 13(6):1139-50. PubMed ID: 25858425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation.
    Parguiña AF; Alonso J; Rosa I; Vélez P; González-López MJ; Guitián E; Eble JA; Loza MI; García Á
    Blood; 2012 Dec; 120(26):e117-26. PubMed ID: 23053573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2.
    Watson AA; Brown J; Harlos K; Eble JA; Walter TS; O'Callaghan CA
    J Biol Chem; 2007 Feb; 282(5):3165-72. PubMed ID: 17132623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.
    Tsukiji N; Osada M; Sasaki T; Shirai T; Satoh K; Inoue O; Umetani N; Mochizuki C; Saito T; Kojima S; Shinmori H; Ozaki Y; Suzuki-Inoue K
    Blood Adv; 2018 Sep; 2(17):2214-2225. PubMed ID: 30190281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice.
    Shirai T; Inoue O; Tamura S; Tsukiji N; Sasaki T; Endo H; Satoh K; Osada M; Sato-Uchida H; Fujii H; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2017 Mar; 15(3):513-525. PubMed ID: 28028907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The platelet receptor CLEC-2 is active as a dimer.
    Watson AA; Christou CM; James JR; Fenton-May AE; Moncayo GE; Mistry AR; Davis SJ; Gilbert RJ; Chakera A; O'Callaghan CA
    Biochemistry; 2009 Nov; 48(46):10988-96. PubMed ID: 19824697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
    Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N
    PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha.
    Bergmeier W; Bouvard D; Eble JA; Mokhtari-Nejad R; Schulte V; Zirngibl H; Brakebusch C; Fässler R; Nieswandt B
    J Biol Chem; 2001 Jul; 276(27):25121-6. PubMed ID: 11352922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
    Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N
    Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
    Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
    Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal cells activate the platelet receptor CLEC-2 through podoplanin.
    Christou CM; Pearce AC; Watson AA; Mistry AR; Pollitt AY; Fenton-May AE; Johnson LA; Jackson DG; Watson SP; O'Callaghan CA
    Biochem J; 2008 Apr; 411(1):133-40. PubMed ID: 18215137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis.
    Inoue O; Hokamura K; Shirai T; Osada M; Tsukiji N; Hatakeyama K; Umemura K; Asada Y; Suzuki-Inoue K; Ozaki Y
    PLoS One; 2015; 10(9):e0139357. PubMed ID: 26418160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.